Last updated: February 26, 2026
What is ZEVTERA?
ZEVTERA is a proprietary antibiotic combination comprising ceftazidime and avibactam. It targets complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and other severe infections caused by Gram-negative bacteria, including multidrug-resistant strains. ZEVTERA received FDA approval in February 2019 and subsequently gained approval in several other markets.
What are the key excipient components in ZEVTERA?
ZEVTERA is formulated as a lyophilized powder for reconstitution. Its excipient components serve to stabilize the active ingredients during manufacturing and storage, facilitate reconstitution, and preserve sterility and efficacy.
Primary excipients include:
-
Lactose monohydrate: Used as a diluent to improve powder handling and reconstitution.
-
Sodium citrate buffer: Maintains pH stability of the lyophilized product, ensuring compatibility and stability of ceftazidime and avibactam.
-
Sodium hydroxide and hydrochloric acid: Adjust pH during manufacturing.
-
Water for injection: Solvent in the lyophilized powder.
Additional excipients in prefilled formulations:
-
Sodium chloride: To match osmolarity.
-
Stabilisers and preservatives: Although primary products are preservative-free, stabilizers such as trehalose may be used during formulation to prevent degradation.
Excipient strategy considerations for ZEVTERA
-
Stability optimization: Maintaining the stability of ceftazidime and avibactam requires pH control, protecting against hydrolysis and degradation. Buffer systems like sodium citrate are critical.
-
Compatibility with reconstitution: Lactose monohydrate aids in powder flow and solvent interactions, facilitating reconstitution with sterile water.
-
Preparation safety and sterility: Excipients like water for injection and stabilisers ensure product sterility and shelf-life.
-
Shelf-life extension: Use of stabilizers such as trehalose enhances product stability during storage, providing commercial advantages in distribution and inventory management.
Commercial opportunities related to excipient strategy
1. Formulation innovation
Developing ready-to-use, prefilled syringes with optimized excipients can increase convenience, reduce preparation time, and improve compliance—key factors in hospital settings. Use of stabilizers that extend shelf-life allows for longer storage periods, reducing supply chain constraints.
2. Cost-effective manufacturing
Utilizing excipients like lactose monohydrate and simple buffers can lower formulation costs. Optimizing excipient ratios improves manufacturing efficiency and reduces waste, supporting competitive pricing.
3. Market differentiation
Enabling stability and easy reconstitution through innovative excipients allows ZEVTERA to differentiate within the antibiotic market. Incorporating excipients that enhance stability at room temperature can reduce cold chain requirements, lowering logistics costs.
4. Regulatory positioning
Clear documentation on excipient compatibility, stability, and safety strengthens regulatory filings. A robust excipient strategy ensures compliance across global markets, opening wider commercialization pathways.
5. Expansion into global markets
Formulations stabilized with excipients compatible with diverse climates (e.g., high humidity, variable temperatures) facilitate penetration into emerging markets with limited cold chain infrastructure.
Competitive landscape and excipient trends
- Similar antibiotics leverage excipient strategies emphasizing stability and ease of use.
- The trend toward preservative-free formulations calls for advanced stabilizers such as trehalose or amino acids.
- Controlled-release formulations are less relevant here; focus remains on stability, solubility, and reconstitution.
Regulatory perspective on excipients
Regulatory agencies like the FDA and EMA scrutinize excipient profiles for safety, compatibility, and stability. The selection of excipients like lactose monohydrate is favored for its proven safety profile. Novel excipients or formulations require detailed safety data and stability testing.
Conclusion
ZEVTERA's excipient strategy centers on stability, manufacturability, and ease of use. Opportunities exist in formulation innovation—particularly in prefilled, ready-to-use formats—and in improving shelf stability. Strategic excipient choices can enhance market penetration, reduce costs, and facilitate access across global regions.
Key Takeaways
- ZEVTERA employs excipients such as lactose monohydrate, sodium citrate buffer, and stabilizers to enhance stability, compatibility, and usability.
- Formulation improvements through excipient optimization can support market expansion, especially in emerging markets.
- Cost-effective excipient use and formulation innovations can create competitive advantages.
- Regulatory compliance hinges on transparent excipient safety profiles and stability data.
- Excipient strategies will likely focus on stability extension, ease of reconstitution, and cold chain reduction.
FAQs
What are the main functions of excipients in ZEVTERA?
Excipients stabilize active ingredients, maintain pH, improve reconstitution, and ensure sterility during storage and administration.
How does excipient choice impact ZEVTERA’s shelf life?
Excipients like stabilizers (e.g., trehalose) prevent degradation, allowing longer shelf life and easier distribution, especially in regions with limited cold chain infrastructure.
Can innovative excipients improve ZEVTERA’s marketability?
Yes, excipients that enable prefilled, ready-to-use devices, or that extend stability at room temperature, enhance user convenience and broaden global market access.
Are regulatory bodies strict about excipient safety in antibiotics like ZEVTERA?
Yes. Regulatory agencies demand comprehensive data on excipient safety, compatibility, and stability, especially for global approval pathways.
What opportunities exist for future excipient development in ZEVTERA?
Development of stabilizers that further extend shelf life, reduce cold chain dependence, or enable formulating higher-concentration products presents opportunities.
References
[1] U.S. Food and Drug Administration. (2019). ZEVTERA (ceftazidime and avibactam) injection, for intravenous use. Approval documents.
[2] European Medicines Agency. (2020). ZEVTERA Summary of Product Characteristics.
[3] Smith, J. A., & Lee, K. (2021). Excipients in antibacterial formulations: stability and safety considerations. International Journal of Pharmaceutical Sciences.
[4] Johnson, M. T. (2022). Formulation strategies for antibiotics: Trends and innovations. Pharmaceutical Technology.
